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Abstract
Chikungunya virus (CHIKV) is an alphavirus that infects millions of people every year, especially
in the developing world. The selective expression of recombinant CHIKV capsid and envelope
proteins results in the formation of self-assembled virus-like particles (VLPs) that have been
shown to protect nonhuman primates against infection from multiple strains of CHIKV. This study
describes the characterization, excipient screening, and optimization of CHIKV VLP solution
conditions towards the development of a stable parenteral formulation. The CHIKV VLPs were
found to be poorly soluble at pH 6 and below. Circular dichroism, intrinsic fluorescence, and static
and dynamic light scattering measurements were therefore performed at neutral pH, and results
consistent with the formation of molten globule structures were observed at elevated temperatures.
A library of GRAS excipients was screened for their ability to physically stabilize CHIKV VLPs
using a high-throughput turbidity based assay. Sugars, sugar alcohols, and polyanions were
identified as potential stabilizers and the concentrations and combinations of select excipients
were optimized. The effects of polyanions were further studied, and while all polyanions tested
stabilized CHIKV VLPs against aggregation, the effects of polyanions on conformational stability
varied.
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Introduction
CHIKV is a positive, single-stranded RNA alphavirus that belongs to the Togaviridae family
of viruses 1 and infects millions of individuals each year.2 Symptoms include rash, fever,
and blisters; excruciating joint pain, however, is the hallmark of the disease and can last for
months or years beyond other symptoms.3 The virus is rarely fatal (approximately 0.1% of
all cases), although serious symptoms such as respiratory failure and brain infections have
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been reported. The more severe symptoms primarily effect the elderly and those with other
medical conditions.4 The morbidity of this disease, as a result of the lingering joint pain and
inflammation, results in significant economic losses and reductions in quality of life.5,6
Currently, no vaccine or anti-viral therapy exists, and CHIKV is treated with painkillers and
general anti-inflammatories.4
CHIKV was first recognized in Tanzania in 1952,7 and historically outbreaks have been
limited to developing countries.8 Recently, however, outbreaks have occurred in the
developed world, and this has led to increased interest in understanding the disease for the
purpose of establishing preventative and therapeutic measures. In 2005, 40% of the
population Réunion, a French island off the coast of Madagascar, was infected with the
disease,9 and in 2007, the first European outbreak occurred in Italy.10–12 CHIKV can be
transmitted by the Asian tiger mosquito (Aedes albopictus),13 and the spread of this
mosquito due to shipping and transport14 creates an environment in which CHIKV
outbreaks are more likely to occur in places where the disease was uncommon in the past.15
In 2008 the Vaccine Research Center at the National Institutes of Health initiated
development of a vaccine against CHIKV utilizing virus-like particles (VLPs). The genomic
RNA of CHIKV encodes four nonstructural proteins (nsPs) required for replication and five
polyproteins including a capsid protein (C) and envelope proteins (E3, E2, 6K, and E1).16
Expression of the capsid and envelope proteins (C-E3-E2-6K-E1) in HEK-293 (human
embryonic kidney-293) cells leads to their assembly into VLPs with an external diameter of
approximately 65 nm, as seen by electron microscopy, that resemble alphaviruses.17
Immunization of nonhuman primates with the VLPs produced high-titer neutralizing
antibodies and protected against subsequent infection with two strains of the virus.17
In this work, we characterize the biophysical properties of purified, recombinant CHIKV
VLPs, screen a library of GRAS (generally recognized as safe) excipients as potential
stabilizers against physical degradation, and further optimize and evaluate selected
polyanion excipients with the goal of providing preformulation characterization data for the
development of a stable parenteral vaccine formulation.
Materials and Methods
Sample preparation, concentration determination, and osmolality measurements
Recombinant CHIKV VLPs were expressed and purified by the Vaccine Production
Program at the NIH, using a scaled up process based on that described by Akahata et al.17
CHIKV VLPs were dialyzed from a stock solution of 218 mM sucrose, 7.2 mM K2HPO4,
3.8 mM KH2PO4, pH 7.0 into one of three different buffers: 20 mM citrate-phosphate buffer
(pH 3–8) with an ionic strength of 0.15, 20 mM sodium phosphate buffer with an ionic
strength of 0.15 (pH 7.0), or 10 mM sodium phosphate buffer (pH 7.0) without additional
sodium chloride, as indicated in the text. CHIKV protein concentration was determined
using a BCA Protein Assay Kit (Pierce, Rockford, IL). Excipients were prepared as
concentrated solutions containing buffer to match the VLP. Excipient, VLP, and buffer were
added together to achieve the concentrations indicated in the text. Osmolality measurements
were made using an OSMETTE II (Precision Systems Inc., Natick, MA) osmometer.
Far-UV circular dichroism
CD measurements were performed using a Jasco J-815 Spectrophotometer (Great Dunmow,
UK) equipped with a Peltier temperature controller. Spectra were collected with a scanning
speed of 20 nm/min and a resolution of 1 nm from 195–260 nm using a 0.1 cm path length
cuvette sealed with a Teflon stopper was used to measure 0.2 mg/mL CHIKV VLP solutions
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(on VLP protein basis). The CD signal at 210 nm was collected over a temperature range of
10 to 90 °C at 0.5 °C intervals and a heating rate of 15°C/hr.
Intrinsic fluorescence and static light scattering
A PTI QM-1 spectrofluorometer (Brunswick, NJ) equipped with a four-position Peltier
temperature controlled cell-holder was used to obtain fluorescence emission spectra. A 1 cm
pathlength cuvette was used to measure 0.2 mg/mL CHIKV VLP solutions. No inner filter
corrections were applied. An excitation wavelength of 295 nm was used for simultaneously
measuring light scattering and intrinsic tryptophan fluorescence. Emission spectra were
collected over a range of 305 to 405 nm at a 1 nm/s collection rate. A second
photomultiplier, placed at 180° to the emission detector was used to record light scattering.
Spectra were collected at 2.5 °C intervals from 10 to 87.5°C with a 3 min equilibration at
each temperature. Fluorescence intensity and peak positions were obtained by a mean
spectrum center of mass method, subsequent to buffer subtraction. This provides wavelength
maxima approximately 10°C higher than the actual maxima but with increased precision and
signal to noise ratios compared to traditional peak maxima determinations. Data analysis
was performed using Felix™ (PTI) and Origin (V 7.0) software.
Dynamic light scattering
Dynamic light scattering measurements were made using a Wyatt DynaPro Plate Reader
dynamic light scattering instrument (Santa Barbara, CA). Five, 30 second acquisitions were
collected for each sample, and data were collected continuously with a temperature ramp
rate of 0.14 °C/min from 10–60 °C. Data were analyzed by percent mass using the Rayleigh
spheres model and Dynapro version 7.2 software.
Turbidity assay
A high-throughput turbidity assay was developed to screen a library of GRAS excipients to
identify stabilizers of CHIKV VLPs. An Agilent Cary 100 spectrophotometer was used to
monitor the OD at 350 nm of 0.2 mg/mL CHIKV VLP solutions. Data were collected at 50
°C, at 2 minute intervals for a total time of 2 hours. Percent inhibition was determined by
comparing the maximum observed turbidity of each excipient condition to a control without
excipients.
Results and Discussion
Biophysical characterization of CHIKV VLPs
CHIKV VLPs were initially dialyzed into a 20 mM citrate/phosphate buffer at varying pH
(pH 3–8) with an ionic strength of 0.15. Table 1 summarizes the visual inspection and UV
absorbance analysis of these samples. After dialysis, significant precipitation was visually
observed at pH 3–6; additionally, significant loss of material occurred in pH 3–5 samples
following centrifugation as evidenced by a decrease in UV absorbance compared to control.
Efforts to increase the solubility in this pH range, for example by removing sodium chloride
or adding sucrose, were not successful. The pH 7 and 8 samples remained free of visible
particles after dialysis; additional experiments were performed at pH 7.0. A potential reason
for the observed low solubility below neutral pH is that Alphaviruses have been reported to
undergo a change in conformation below neutral pH, and this change in conformation could
have lower solubility.18,19
To obtain information about the secondary structure of the VLPs, circular dichroism
experiments were performed. Figure 1a shows a CD spectrum of CHIKV VLP in 20 mM
sodium phosphate buffer, pH 7.0 at 10°C. The spectrum indicates that the VLP proteins
adopt a conformation that contains both α-helix and β-sheet secondary structure features. A
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more detailed analysis was not attempted due to the multiprotein nature of the VLPs. The
spectrum displays a minimum at approximately 210 nm. The CD signal at 210 nm was
monitored as a function of temperature from 10°C to 85°C (Figure 1b). A primary structural
transition was observed with an onset of approximately 50.2°C; a second smaller, yet
reproducible, transition with an onset of approximately 52.5°C was also observed.
Intrinsic fluorescence experiments were performed by exciting the tryptophan residues in the
VLPs at 295 nm. Changes in the polarity of the micro-environments of the tryptophan
residues result in changes to both the intensity and peak position of the fluorescence
emission spectra (Figures 2a–c). The mean spectral center of mass method was used to
follow temperature-dependent changes in peak position (Figure 2b). The intensities at these
wavelengths were also monitored (Figure 2c). Both methods show similar structural
transition onsets at approximately 40°C–45°C. This result, in combination with the
previously discussed CD data, suggests the VLPs may possess molten globule like behavior
in the temperature range of 40°C–50°C, identified by a change or loss of tertiary structure
without a loss of secondary structure. It must be noted, however, that the application of the
molten globule state definition to a multi-protein containing virus-like particle has not been
established.
A combination of static (Figure 3a) and dynamic light scattering (Figure 3b) measurements
were made to monitor the aggregation behavior of the VLPs as a function of temperature.
Static light scattering measurements were made concurrently with the intrinsic fluorescence
measurements described above, in which the scattered light was detected at a 90° angle from
the excitation beam using a separate detector. DLS measurements indicate that the VLPs
have a hydrodynamic radius of approximately 33 nm, which agrees well with previously
published EM results in which the VLPs were found to have a diameter of approximately 65
nm.17 Both sets of light scattering results show an increase in scattering at approximately
45–50°C, suggesting that aggregation of the VLPs may be initiated or enhanced by the
tertiary structural transition observed by fluorescence spectroscopy. These results indicate
that the aggregating VLP species display characteristics consistent with a partially folded
(molten globule-like) intermediate.
Excipient screening, optimization, and conformational stability analysis—A
high-throughput turbidity assay was used to screen a library of GRAS excipients for their
ability to affect the colloidal stability the VLPs. This assay evaluated VLP aggregation
kinetics by monitoring the optical density at 350 nm as a function of time at 50°C.
Representative VLP aggregation profiles in the presence of several stabilizers, as well as a
destabilizer, are shown in Figure 4, with the results summarized in Figure 5. Several
different classes of excipients were examined.20 Some classes, such as amino acids and
cyclodextrins, did not exhibit a significant effect on the aggregation of the VLPs, while
detergents such as Tween 80 and Brij 35 increased the rate and extent of aggregation. Eight
stabilizers that either significantly or completely inhibited VLP aggregation were identified
from three classes of excipients including all sugars tested (dextrose, sucrose, trehalose,
lactose), one sugar alcohol (mannitol), and various polyanions (sodium citrate, dextran
sulfate, malic acid). Six of these candidate stabilizers, including at least one from each class,
were selected for further study.
One important component of the CHIKV VLPs that has not been directly investigated in this
study is the role that the integral lipid envelope plays in the spectral transitions and
aggregation processes observed. The lipid layer surrounds the capsid protein core and serves
as an anchor for the glycoprotein spikes of the VLP. It is conceivable that destabilizing
effects of some of the excipients evaluated in this work could be result of partial
destabilization of the lipid bilayer (e.g. surfactant class excipients). The role of the lipid
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bilayer in the VLP-excipient interaction is still relatively unknown, and will hopefully be
elucidated in future works by this and other research groups.
The effect of various concentrations of the lead excipient candidates (dextrose, sucrose,
trehalose, mannitol, sodium citrate, and malic acid) on VLP aggregation was evaluated.
Figure 6 shows results from a concentration optimization of these six excipients. For all
excipients tested here, inhibition of turbidity decreased with concentration. Of the three
sugars tested, dextrose was the most effective; however, dextrose solutions of equal weight
to volume ratio have approximately twice the contribution to osmolarity as disaccharides
like sucrose and trehalose. For example, the osmolarity of a 5% w/v solution of dextrose is
approximately 280 mOsm, whereas the osmolarity of a 10% w/v solution of sucrose or
trehalose is approximately 290 mOsm. Therefore, it may be more appropriate to compare
disaccharides and simple sugars at equimolar concentrations rather than equal weight
volume concentrations. When compared on an equimolar basis, sucrose and trehalose are
more effective at inhibiting the aggregation of CHIKV VLPs than dextrose. In addition,
dextrose is a reducing sugar which may potentially lead to glycation of the proteins in the
VLPs.21 Based on this information, dextrose was eliminated as a lead excipient candidate.
Based on the results of the excipient screening and optimization studies, promising excipient
conditions are listed Table 2. These conditions were selected based on their ability to inhibit
the aggregation of the VLPs, although some conditions possess a high solution osmolarity,
discussed further below. The effects of these stabilizers on the conformational stability of
the VLP were studied by far-UV CD and intrinsic fluorescence; however, no stabilizing
effect on the conformational stability of the VLPs was seen (Figure S1).
Effects of ionic strength on solution osmolality and inhibition of aggregation
by select excipients—As shown in Table 2, many of the stabilizing conditions identified
for CHIKV VLPs possess a high total osmolarity. In the absence of additional excipients,
the osmolality of 20mM sodium phosphate buffer containing NaCl (I =0.15) approaches that
of human plasma (Table 2). The addition of 10% w/v of trehalose or sucrose to this buffer,
increases the osmolality values to 523 and 571 mOsm/kg H2O, respectively. Dextrose and
mannitol 10% w/v solutions increase this value even further, to approximately 900 mOsm/
kg H2O. This effect is not limited to the sugar and sugar alcohol classes, however, as the two
polyanions, malic acid and sodium citrate, 0.1 M solutions have osmolality values of 482
and 506 mOsm/kg H2O, respectively. A lower solution osmolarity is optimally desired for
clinical administration therefore the effect of lowering the solution osmolality on the ability
of these excipients to inhibit CHIKV VLP aggregation was evaluated.
The ionic strength of the buffer was lowered from 0.15 to 0.035 by decreasing the sodium
phosphate concentration from 20 to 10 mM and by eliminating the additional NaCl. The
effects of sodium citrate and malic acid on the aggregation of CHIKV VLPs in both the high
and low ionic strength buffers were then evaluated, as shown in Table 3. As expected, the
osmolality of the lower ionic strength solutions decreases by approximately 220 mOsm/kg
H2O compared to the high ionic strength buffer. Sodium citrate and malic acid both
demonstrated increased inhibition of VLP aggregation in the lower ionic strength buffer
compared to the higher ionic strength buffer. For example, in the presence of 50 mM sodium
citrate, the aggregation of the VLPs is inhibited by 54% in the low ionic strength buffer but
only by 35% at high ionic strength. At concentrations of citrate greater than 100 mM, the
aggregation of VLPs is nearly completely inhibited in the low ionic strength buffer. For
malic acid, at concentrations of 50 or 100 mM, the levels of inhibition of VLP aggregation
are similar in both the low and high ionic strength buffers. At 150 mM and above, however,
nearly complete inhibition of aggregation is observed in the low ionic strength buffers. In
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summary, by lowering the ionic strength of malic acid and sodium citrate solutions, similar
or higher inhibition of VLP aggregation were achieved.
Effects of polyanions on the stability of CHIKV VLP—Several polyanions were
found to stabilize CHIKV VLPs against aggregation, including sodium citrate, malic acid,
and dextran sulfate. We have previously shown that polyanions have the ability to inhibit the
aggregation of several growth hormones.22 In order to test the hypothesis that the protective
effects observed are due to the polyanionic nature of these excipients, additional
experiments were performed with these excipients as well as two other well-known
polyanions, sodium sulfate and heparin. 22–24
The effects of the five polyanions at various concentrations on the turbidity of CHIKV VLP
solutions were evaluated (Figure 7). Sodium citrate and malic acid demonstrated similar
behavior, with nearly complete inhibition of VLP aggregation at concentrations of 100 mM
and above. At 50 mM, however, little protective effect was observed for malic acid, while
sodium citrate induced approximately 50% turbidity inhibition. Higher concentrations (0.15
M) of sodium sulfate were required to achieve maximum stabilizing effects. For dextran
sulfate and heparin, complete inhibition was seen at all concentrations tested here (0.5–10
mM and 1–5 mg/mL, respectively).
The effects of heparin on the stability of CHIKV VLP solutions at lower concentrations
were also studied. Figure 8 shows CD spectra for CHIKV VLP at 10 °C prior to and after
heating to 90°C in the presence of various concentrations of heparin. In the absence of
heparin and in the presence of 1 μg/mL of heparin, significant loss in CD signal is seen after
heating to 90°C and cooling; however, in the presence of 50 or 100 μg/mL heparin,
complete recovery of the CD signal is observed. This result suggests that heparin protects
the secondary structure of CHIKV VLP from temperature induced denaturation at 50 μg/mL
and above.
Figure 9a shows the OD 350 nm of CHIKV VLP solutions in the presence of 1–10 μg/mL
heparin. Maximum protective effects are seen at concentrations of 6 μg/mL and above.
Figure 9b shows the fluorescence peak position as a function of temperature for CHIKV
VLP solutions in the presence of heparin. Even at the lowest concentration tested (1 μg/mL),
significant destabilization of CHIKV VLP by heparin is seen as indicated by the lower
temperature transition onsets.
The above results present an interesting scenario, showing that while heparin inhibits the
aggregation of CHIKV VLP and protects refolding of the secondary structure, heparin also
decreases the thermal stability of the VLP’s overall tertiary structure. Unfortunately, a
concentration of heparin does not appear to exist that inhibits VLP aggregation without
decreasing the VLP conformational stability. To this end, heparin in combination with other
excipients was also examined; in each case, however, the VLP physical stability was not
improved in combination with heparin over that observed for the other excipients alone (data
not shown). Dextran sulfate was also observed to destabilize the structural stability of VLPs
(data not shown).
One important component of the CHIKV VLPs that has not been directly investigated in this
study is the role that the integral lipid envelope plays in the spectral transitions and
aggregation processes observed. The lipid layer surrounds the capsid protein core and serves
as an anchor for the glycoprotein spikes of the VLP. It is conceivable that destabilizing
effects of the stress conditions and some of the excipients evaluated in this work could be
result of partial destabilization of the lipid bilayer (e.g. surfactant class excipients). The role
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of the lipid bilayer in the VLP-excipient interaction is still relatively unknown, and will
hopefully be elucidated in future works by this and other research groups.
Conclusions
Biophysical characterization of CHIKV VLPs was performed at neutral pH values, as poor
solubility was observed at acidic pH (pH 6 and below). CHIKV VLPs with a radius of 33
nm were detected in solution by dynamic light scattering, which closely agrees with
previously published EM results. Circular dichroism spectra indicate that CHIKV VLPs
adopt a mixed α-helix and β-sheet conformation. Thermal unfolding studies suggest the
presence of molten globule-like behavior between 45°C and 50 °C, a unique observation for
VLPs. After unfolding of the tertiary structure, CHIKV VLP aggregates were observed
visually as well as by static and dynamic light scattering.
A high-throughput turbidity-based assay was developed, and a screen of a GRAS excipient
library using this method identified several stabilizers. Trehalose, sucrose, dextrose,
mannitol, sodium citrate, and malic acid were identified as lead stabilizers and further tested
for concentration optimization and conformational stability analysis. Studies of the effect of
ionic strength on CHIKV VLP stability suggest that citrate and malic acid are more effective
stabilizers in the absence of NaCl as an ionic strength modifier. Based on the efficacy of
citrate and malic acid, additional polyanions were evaluated; all polyanions tested inhibited
the aggregation of CHIKV VLP. Interestingly, malic acid and sodium citrate did not
destabilize the conformational stability of CHIKV VLPs, while heparin and dextran sulfate
significantly decreased the structural stability.
The data presented in this work suggest the following formulation may be acceptable for
long-term stability of CHIKV VLP: 10 mM sodium phosphate, pH 7.0 along with(one or
more of) 10% (w/v) trehalose, 10% w/v sucrose, 0.1 M sodium citrate, and/or 0.1M malic
acid. Optimization studies evaluating excipient combinations, as well as long-term stability
studies, are also recommended.
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Circular dichroism analysis of CHIKV VLPs in 20 mM sodium phosphate buffer (I=0.15),
pH 7.0, at 200 μg/mL protein. The far-UV CD spectrum (a) indicates mixed α-helix and β-
sheet content. The CD signal at 210 nm was followed as a function of temperature from 10–
87.5 °C (b). Error bars indicate standard deviation between two measurements.
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Intrinsic fluorescence data for CHIKV VLPs in 20 mM sodium phosphate buffer (I=0.15),
pH 7.0, at 200 μg/mL protein. Tryptophan residues were excited at 295 nm, and the
emission intensities from 305–405 nm were collected (a). The emission spectra were
collected from 10–87.5°C and used to calculate the mean spectral center of mass peak
positions (b) and intensities (c). Error bars indicate standard deviation between two
measurements.
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Light Scattering data for CHIKV VLPs in 20 mM sodium phosphate buffer (I=0.15), pH 7.0
as a function of temperature. A VLP concentration of 200 μg/mL was used. Static light
scattering (a) was collected concurrently with intrinsic fluorescence data by using a separate
detector at a right-angle to the excitation. The hydrodynamic radius of the VLP particles was
determined using dynamic light scattering (b). Error bars indicate standard deviation
between two measurements.
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Representative data from a high-throughput turbidity assay used to screen the ability of
various excipients to inhibit CHIKV VLP aggregation. The OD at 350 nm of a 200 μg/mL
solution of CHIKV VLP in 20 mM sodium phosphate buffer (I=0.15), pH 7.0 was measured
at 50°C for 2 hours in the presence of 27 different excipients. Results are summarized in
Figure 5.
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Summary results from a screen of 27 GRAS excipients to inhibit VLP aggregation.
Turbidity inhibition is defined as the level of maximum turbidity observed for a sample in
the presence of the indicated excipient relative to that observed in the control without
excipient by monitoring the OD at 350 nm. Error bars indicate the standard deviation of at
least two measurements. Turbidity inhibition by 20% (w/v) dextrose, 20% (w/v) sucrose, 0.2
M sodium citrate, 20% (w/v) mannitol, 20% (w/v) trehalose, 20% (w/v) lactose, and 0.15 M
malic acid were found to be significantly different from the control by unpaired t-test
(p<0.02). A 200 μg/mL solution of CHIKV VLPs in 20 mM sodium phosphate buffer
(I=0.15), pH 7.0 was monitored at 50°C for 2 hours.
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Concentration optimization of excipient’s ability to inhibit CHIKV VLP aggregation as
measured by turbidity assay. Excipients were selected based on the results of the initial
turbidity screen (See Figure 5). Results shown are from a single experiment. Typical error is
+/− 10%.
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Turbidity inhibition of CHIKV VLPs by addition of various polyanions. Turbidity inhibition
is defined as the level of maximum turbidity observed of a sample in the presence of the
indicated excipient relative to that observed in the control without excipient by monitoring
the OD at 350 nm. Error bars indicated the standard deviation of at least two measurements.
Turbidity inhibition by all tested concentrations of sodium citrate (p<0.01), and dextran
sulfate (p<0.004) as well as 0.1–0.25 M malic acid (p<0.01), 0.1–0.25 M sodium sulfate
(p<0.04), and 1–4 mg/mL heparin (p<0.02) were found to be significantly different from the
control by unpaired t-test. A 200 μg/mL solution of CHIKV VLP in pH 7 sodium phosphate
buffer (I=0.15) was monitored at 50°C for 2 hours.
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CD spectra of CHIKV VLP in the absence and presence of heparin. Samples were measured
at 10°C before (solid curve) and after heating to 87.5°C followed by subsequent cooling
(broken curve). Refolding was performed without heparin (a) and in the presence of 1 μg/
mL (b), 50 μg/mL, and 100 μg/mL (c).). Results shown are from a single experiment.
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Turbidity (a) and mean spectral mass positions (b) of CHIKV VLP solutions containing
heparin at concentrations indicated in figure legends. The OD at 350 nm was measured at
50°C in the presence of 1–10 μg/mL heparin for 2 hours. Emission spectra were collected
from 305–405 nm with excitation at 295 nm as a function of temperature. 200 μg/mL
solutions of CHIKV VLP in 10mM sodium phosphate buffer, pH 7.0 were measured in the
presence of 1–100 μg/mL heparin. Results shown are from a single experiment.
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Table 1
CHIKV VLP solution absorbance at 280 nm after dialysis into various buffers.
Samplea A280 nme Visual Examination
Stockb 0.91 clear solution
pH 3 0.14 precipitation
pH 4 0.06 precipitation
pH 5 0.02 precipitation
pH 5c 0.02 precipitation
pH 5d 0.07 precipitation
pH 6 0.42 precipitation
pH 7 0.58 clear solution
pH 8 0.56 clear solution
a
The samples were dialyzed from stock into a 20 mM citrate/phosphate buffer at the indicated pH with and ionic strength of 0.15 achieved by
adding NaCl. After dialysis, the sample volume increased approximately 1.5 times. Results shown are from a single experiment.
b
218mM sucrose, 7.2 mM K2HPO4, 3.8 mM KH2PO4, pH 7.0
c
Dialyzed without additional NaCl.
d
Dialyzed without additional NaCl + 10% w/v sucrose.
e
The A280 nm of the supernatant was measured after centrifugation at 13,800 × g for 10 minutes in a ThermoScientific Sorvall microcentrifuge.
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Table 2
Candidate excipient conditions for stabilizing CHIKV VLPs and corresponding osmolality values.a
Excipient Osmolality (mOsm/kg H2O)b
- 252±0
10% (w/v) trehalose 523±4
10% sucrose (w/v) 571±27
10% dextrose (w/v) 895±4
10% mannitol (w/v) 898±4
0.1 M malic acid 482±2
0.1 M sodium citrate 506±5
a
20 mM sodium phosphate buffer with an ionic strength of 0.15 (NaCl) at pH 7 plus the indicated excipients.
b
Standard deviations of three measurements are reported. All osmolality values for the excipient containing samples were found to be significantly
different from the sample without excipient by unpaired t-test (p<0.0001).
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